Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q4 2026 Earnings Presentation
18 slides from Angiodynamics's earnings presentation, Jul 14, 2026
Slide 1: Fourth Quarter and Full Year 2026 Earnings Results
Fourth Quarter and Full Year 2026 Earnings Results July 14, 2026
Slide 2: Forward looking statements
Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Q4 FY 2026 Key Takeaways
Q4 FY 2026 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. YoY Revenue Total Med Tech Med Device Growth* +8.0% +16.7% +1.1% Med Tech YoY Auryon Mech Thrombectomy NanoKnife Probes Revenue Growth* +14.4% -1.1% +47.0% • Net sales of
Slide 4: Q4 FY 2026 Financial Snapshot
Q4 FY 2026 Financial Snapshot Net Sales Segment Revenue Contribution $86.6 $80.2 Q4 25 Q4 26 $41.8 45% $35.8 +16.7% 48% Pro Forma Growth 52% 55% Med Device Med Tech Med Device Med Tech +1.1% Segment Gross Margin $44.4 $44.8 Pro Forma Growth 44.4% 64.3% Q4 25 Q4 26 Med Device Med Tech Med Device Med
Slide 5: FY 2026 Key Takeaways
FY 2026 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. YoY Revenue Total Med Tech Med Device Growth* +9.4% +18.4% +2.5% Med Tech YoY Auryon Mech Thrombectomy NanoKnife Probes Revenue Growth* +17.7% 13.4% +28.7% • Net sales of $32
Slide 6: FY 2026 Financial Snapshot
FY 2026 Financial Snapshot Net Sales Segment Revenue Contribution $320.2 FY 25 FY 26 $292.7 43% $150.0 +18.4% 47% 53% $126.7 Pro Forma Growth 57% Med Device Med Tech Med Device Med Tech +2.5% Segment Gross Margin $166.0 $170.2 Pro Forma Growth 46.7% 63.6% FY 25 FY 26 Med Device Med Tech Med Device M
Slide 7: Demonstrated Med Tech Growth Execution
Demonstrated Med Tech Growth Execution Pro Forma Fiscal Year Net Sales ($M) $320 $293 $271 $257 Med Tech $235 $150 ~47% of $206 $127 +18.4% $186 $96 $106 Total Med Tech $79 $56 ~22% of Total $41 $157 $161 $165 $166 $170 $145 $151 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 A Med Device Med Tech 7
Slide 8: Q4 FY 2026 MedTech Performance Snapshot
Q4 FY 2026 MedTech Performance Snapshot +16.7% growth driven by solid commercial execution and continued portfolio adoption Q4 FY 2026 Sales ($M) YoY Growth Key Highlights Total Auryon $17.8 14.4% • Auryon: Double-digit growth for the 20th straight quarter, driven by our hospital atherectomy shift,
Slide 9: Full Year FY 2026 MedTech Performance Snapshot
Full Year FY 2026 MedTech Performance Snapshot +18.4% growth driven by solid commercial execution and continued portfolio adoption FY 2026 Sales ($M) YoY Growth Key Highlights Total Auryon $66.9 17.7% • Auryon: Capped the year with strong double-digit growth, extending its multi-year track record as
Slide 10: Fiscal Year 2027 Guidance
Fiscal Year 2027 Guidance supported by balance sheet strength FY 2026 Net Sales ($M) FY 2027 Financial Guidance* $336 - $341 Current $320 Metric Guidance Net Sales $336.0M - $341.0M +12 - 15% Med Tech Med Tech Net Sales Growth +12% - 15% Med Device Net Sales Growth Flat Gross Margin 54% – 55% Flat A
Slide 11: Strong Product & Clinical Pipeline
Strong Product & Clinical Pipeline Leveraging our leading platforms to fuel innovation, market expansion, and long-term shareholder value in key growth markets FY26 & Earlier FY27 – FY31 Platform $7.2B US TAM $10.9B US TAM Peripheral Artery Disease: $800M US TAM IVL Indication DVT: $2.8B US TAM Coro
Slide 12: Ongoing Clinical Initiatives to Support Growth
Ongoing Clinical Initiatives to Support Growth Initiative Overview Purpose A randomized controlled trial of the Auryon Atherectomy System + balloon angioplasty vs. standard angioplasty Increased utilization within the AMBITION BTK alone for below-the-knee lesions with critical limb below the knee cr
Slide 13: Appendix
Appendix 13
Slide 14: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousand, except per share data) 14
Slide 15: Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss
Reconciliation of Net Loss and Diluted Loss Per Reconciliation of Net Loss and Non-GAAP Share to Non-GAAP Adjusted Net Loss and Pro Forma Adjusted Net Loss to Adjusted Diluted Loss Per Share and Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Net Loss and Diluted Loss Per Share (in thousands
Slide 16: Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss
Reconciliation of Net Loss and Diluted Loss Reconciliation of Net Loss and Non-GAAP Per Share to Non-GAAP Adjusted Net Loss Pro Forma Adjusted Net Loss to Adjusted and Diluted Loss Per Share and Pro Forma EBITDA and Pro Forma Adjusted EBITDA Adjusted Net Loss and Diluted Loss Per Share (in thousands
Slide 17: Detail of “Acquisition, Restructuring and Other Items, net”
Detail of “Acquisition, Restructuring and Other Items, net” (in thousands) 17
Slide 18: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) 18